{
    "root": "fe187ba0-468c-4a07-90b9-f8d6123673fa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Alprazolam",
    "value": "20250515",
    "ingredients": [
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "DIETHYLHEXYL SODIUM SULFOSUCCINATE",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "Alprazolam tablets are indicated for the: \n                  \n                     \n                        •acute treatment of generalized anxiety disorder (GAD) in adults. \n                     \n                        •treatment of panic disorder (PD), with or without agoraphobia in adults.",
    "contraindications": "• Generalized Anxiety Disorder: ( 2.1 ) ○ Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. ○ Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. ○ Use the lowest possible effective dose and frequently assess the need for continued treatment. • Panic Disorder: Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. ( 2.2 ) • When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.3 , 5.2 ) • See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions": "Product:    50090-1864\n                  NDC:    50090-1864-2   14 TABLET in a BOTTLE\n                  NDC:    50090-1864-0   30 TABLET in a BOTTLE\n                  Product:    50090-2819\n                  NDC:    50090-2819-1   90 TABLET in a BOTTLE\n                  Product:    50090-2896",
    "adverseReactions": "Alprazolam is contraindicated in patients:\n                  \n                     \n                        •with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported [see Adverse Reactions (6.2)]. \n                     \n                        •taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.6), Warnings and Precautions (5.5), Drug Interactions (7.1)]"
}